MiMedx Group, Inc. announced that its board of directors has appointed Joseph H. Capper as the company's chief executive officer, effective immediately. Todd Newton, who has served as the company's interim CEO since September 2022 will remain in his role on the board of directors. Mr. Capper joins the company with nearly 30 years of MedTech and Life Sciences experience.

He has successfully led several organizations, most recently serving as the CEO of BioTelemetry, where he guided the company through a significant turn-around, taking BioTelemetry from a micro-cap company and culminating with its acquisition by Royal Philips for $2.8 billion. Prior to BioTelemetry, Joe served as President and CEO of both Home Diagnostics and CCS Medical, which were also acquired at substantial premiums from Mr. Capper's entry. Joe brings with him a wealth of commercial experience, having held several leadership roles earlier in his career during the decade he spent with Bayer AG.

Additionally, Mr. Capper was an officer in the U.S. Navy serving with distinction as a naval aviator. He received his undergraduate degree in Accounting from West Chester University and MBA in International Finance from George Washington University.